Skip to main content
Equibles

SOPH · SOPHiA GENETICS SA · Webcasts, Transcripts & Audio

Track SOPH — free

Use SOPH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SOPH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.39 +0.32 (+3.98%)
Rebalance outlook locked
Market Cap
$709.97M
Shares
85.13M
Volume · Oct 5 1.18M Avg daily vol (3M) 525.46K

SOPHiA GENETICS SA Webcasts

Earnings calls, investor updates, investor days and conferences for SOPHiA GENETICS SA (SOPH), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲29% $15.05M −$21.40M '23 Q2 23-06-30 ▲5% $15.81M −$15.19M '24 Q2 24-06-30 LATEST ▲15.9% $18.32M −$22.41M '25 Q2 25-08-05
Earnings call
FY26 · Q2
2026-08-04
SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript
Confident tone AstraZeneca CDX Deals Customer Implementations and Backlog Capital Raise and Balance Sheet
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
SOPHiA GENETICS SA (SOPH) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
SOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call Transcript
Confident tone SOPHiA DDM Platform and AI MSK Access and Biopharma Path to Profitability and Efficiency
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-03
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
Confident tone Customer wins and U.S. growth Guidance and 2026 outlook Platform modernization and scalability
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
SOPHiA GENETICS SA (SOPH) Q3 2025 Earnings Call Transcript
Confident tone MSK-ACCESS liquid biopsy franchise Companion diagnostic (CDx) partnerships New customer signings and expansion
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
SOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call Transcript
Confident tone MSK-ACCESS liquid biopsy application Revenue growth and BioPharma headwinds AstraZeneca partnership
Revenue
$18.32M
▲ 15.9% YoY
Diluted EPS
$-0.33
Gross margin
67.0%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
SOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call Transcript
Confident tone MSK-ACCESS and MSK-IMPACT applications Biopharma partnerships Platform scalability and AI
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
SOPHiA GENETICS SA (SOPH) Q4 2024 Earnings Call Transcript
Confident tone 2025 Growth Drivers New Application Launches (MSK) 2025 Financial Guidance
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript
Positive tone Leadership changes Cost discipline and cash burn MSK-ACCESS powered with SOPHiA DDM
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
SOPHiA GENETICS SA (SOPH) Q2 2024 Earnings Call Transcript
Positive tone BioPharma headwinds and restructuring Platform and product launches New customer signings and bookings
Revenue
$15.81M
▲ 5% YoY
Diluted EPS
$-0.23
Gross margin
68.2%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
SOPHiA GENETICS SA (SOPH) Q1 2024 Earnings Call Transcript
Positive tone Backlog, bookings, and new logos Biopharma business and deal delays Applications: solid tumor, HRD, liquid biopsy, MSK Access
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
SOPHiA GENETICS SA (SOPH) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
SOPHiA GENETICS SA (SOPH) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
SOPHiA GENETICS SA (SOPH) Q2 2023 Earnings Call Transcript
Revenue
$15.05M
▲ 29% YoY
Diluted EPS
$-0.33
Gross margin
66.7%
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
SOPHiA GENETICS SA (SOPH) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
SOPHiA GENETICS SA (SOPH) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
SOPHiA GENETICS SA (SOPH) Q3 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
SOPHiA GENETICS SA (SOPH) Q2 2022 Earnings Call Transcript
Revenue
$11.67M
Diluted EPS
$-0.39
Gross margin
65.3%
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
SOPHiA GENETICS SA (SOPH) Q1 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
SOPHiA GENETICS SA (SOPH) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
SOPHiA GENETICS SA (SOPH) Q3 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–21 of 21 webcasts
Key facts CIK 1840706 CUSIP H82027105 13F (30d) 1 filings 1 filers Visit website Investor relations